# BPC-157 Dosage Research Context — Preclinical Protocols, Routes, and Pharmacokinetics > Preclinical research doses, routes of administration, pharmacokinetic data, and half-life findings for BPC-157 — documented as research context only. For research purposes only. ## Research Context Only BPC-157 is not approved for human use by the FDA or any other major regulatory agency as of 2025. Every dose figure on this page describes what was studied in preclinical animal models or reported in small human pilot studies — not what is recommended, prescribed, or appropriate for human administration. The framing throughout is 'studied at X µg/kg in species Y via route Z.' Nothing here constitutes medical advice, clinical guidance, or a prescription. ## Preclinical Dose Range and Routes Studied The most commonly used preclinical dose in rodent models is 10 micrograms per kilogram (10 µg/kg) by intraperitoneal injection. This dose appears across gastric protection, liver protection, tendon healing, anastomosis healing, NSAID counteraction, and ischemia-reperfusion protection studies [1, 8, 12]. A lower dose of 10 nanograms per kilogram (10 ng/kg) — one thousandth of the 10 µg/kg dose — has been studied extensively and found equipotent to the higher dose in multiple models. Achilles tendon-to-bone healing, intestinal anastomosis promotion, liver protection, and NSAID-toxicity counteraction have all been documented at 10 ng/kg as well as at 10 µg/kg [11, 18]. An ultra-low dose of 10 picograms per kilogram (10 pg/kg) was studied in the Achilles detachment model, producing measurable improvements in Achilles Functional Index and biomechanical parameters [11]. For oral administration, the primary research model uses drinking water supplemented to a concentration of 0.16 µg/mL, delivering approximately 12 mL per rat per day. Oral-route effects have been documented for gastrointestinal protection, liver protection, NSAID counteraction, and anastomosis healing [1, 12]. **Routes studied in the literature:** intraperitoneal, oral gavage, drinking water, intramuscular, intravenous, subcutaneous, topical cream (1 µg/g), intravesicular, intra-articular, local bath application. ## Pharmacokinetics: Half-Life, Bioavailability, and Clearance The most comprehensive published pharmacokinetic dataset is He et al. (2022) in Frontiers in Pharmacology, characterizing ADME across three escalating intramuscular doses in both rats and beagle dogs [13]: - **Elimination half-life:** <30 minutes in both species (IM) - **Tmax:** ~3 minutes in rats, 6–9 minutes in beagle dogs (IM) - **Bioavailability:** 14–19% in rats, 45–51% in dogs (IM) - **Kinetics:** Linear across all tested doses — no accumulation, no saturation - **Distribution:** Primary to kidney, liver, stomach, spleen, thymus; minimal brain accumulation - **Excretion:** Urine and bile - **Metabolism:** Primarily to proline and other standard amino acids — re-enter normal amino acid pathways, no toxic metabolites In the human IV infusion pilot (20 mg), plasma concentrations returned to baseline within 24 hours [6]. ## Human Pilot Dosing: What Was Administered **Lee and Burgess (2025) — IV infusion:** 10 mg BPC-157 by one-hour IV infusion on day one, 20 mg on day two, in two healthy adult volunteers [6]. No adverse events. Normal metabolic panel, ECG, thyroid, vitals throughout. **Lee and Padgett (2021) — intra-articular knee:** BPC-157 by direct intra-articular injection in 17 patients with chronic knee pain [14]. 87.5% significant improvement at 6–12 months. No adverse events. **Intravesicular study — interstitial cystitis:** BPC-157 instilled into the bladder via catheter [21]. No adverse effects reported. These are pilot datasets establishing that BPC-157 has been administered to humans by three routes without documented adverse events. They do not constitute clinical-grade safety data. ## References [1] Sikiric P, et al. Stable Gastric Pentadecapeptide BPC 157 as a Therapy and Safety Key. Pharmaceuticals (Basel). 2025. DOI: 10.3390/ph18060928 [2] Jozwiak M, et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide. Pharmaceuticals (Basel). 2025. DOI: 10.3390/ph18020185 [6] Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Alt Ther Health Med. 2025. DOI: 10.12659/AOT.948001 [8] Demirtas H, et al. Protective Effects of BPC 157 in Ischemia-Reperfusion Injury. Medicina (Kaunas). 2025. DOI: 10.3390/medicina61020291 [11] Krivic A, et al. Achilles detachment in rat and BPC 157. J Orthop Res. 2006. DOI: 10.1002/jor.20096 [12] Seiwerth S, et al. BPC 157 and Wound Healing. Front Pharmacol. 2021. DOI: 10.3389/fphar.2021.627533 [13] He L, et al. Pharmacokinetics of BPC 157 in rats and dogs. Front Pharmacol. 2022. DOI: 10.3389/fphar.2022.1026182 [14] Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Alt Ther Health Med. 2021. DOI: 10.12659/AOT.932720 [18] Bajramagic S, et al. BPC 157 and Intestinal Anastomoses Therapy in Rats. Pharmaceuticals (Basel). 2024. DOI: 10.3390/ph17081081 [21] Yuan C, et al. From Regeneration to Analgesia: The Role of BPC-157. Int J Mol Sci. 2026. DOI: 10.3390/ijms27062876 --- For research purposes only. Not for human consumption. This site does not sell any product and is not affiliated with any vendor.